SEARCH RESULTS

6113 RESULTS

John Trojanowski, 75, a Giant in the Field of Neuropathology

COMMUNITY NEWS 2022-02-11 Community News Scientists the world over are shocked and saddened to learn that John Q. Trojanowski passed away on February 8, at the altogether too-young age of 75. The cheerful and unmovable object to the unstoppable force that is his wife and lifelong

CMS Plans to Limit Aduhelm Coverage to Clinical Trials

RESEARCH NEWS 2022-01-20 Research News After months of uncertainty, the hammer fell for Biogen: In a draft decision released January 11, the Centers for Medicare and Medicaid Services proposed to cover the anti-amyloid antibody Aduhelm only in the context of clinical trials appro

Sylvain Lesné, Who Found Aβ*56, Accused of Image Manipulation

COMMUNITY NEWS 2022-07-22 Community News The Alzheimer’s field was rocked this week by allegations against Sylvain Lesné at the University of Minnesota, Minneapolis. Lesné stands accused of manipulating data images in multiple papers, including his 2006 Nature paper identifying Aβ

Aducanumab Approved to Treat Alzheimer’s Disease

RESEARCH NEWS 2021-06-07 Research News In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid antibody aducanumab, now called Aduhelm,

Dale Schenk, 59, Pioneer of Alzheimer’s Immunotherapy

COMMUNITY NEWS 2016-10-03 Community News Dale Schenk, a leader in the field of Alzheimer’s disease immunotherapy passed away Friday, September 30, after a battle with pancreatic cancer that started in 2014. Schenk had been working until recently. He was 59. Dale Schenk at the Siem

No Easy Answers on Clinical Meaningfulness of Alzheimer’s Treatments

RESEARCH NEWS 2023-02-16 Research News The slight slowing of cognitive decline achieved by Leqembi and perhaps by Aduhelm has revived debate around how much change is needed to be “clinically meaningful.” Two recent papers—one a report from a working group convened by the Alzheim

Field Loses Beloved Wizard of Glia, Ben Barres, 63

COMMUNITY NEWS 2018-01-04 Community News Alzheimer’s researchers, and colleagues across neuroscience, are mourning the loss of Ben Barres, who died December 27 of pancreatic cancer at the age of 63. First diagnosed in March 2016, Barres continued pursuing the work he loved and dis

Field Loses GSM Developer Steven Wagner, 64

COMMUNITY NEWS 2022-03-17 Community News The Alzheimer’s research community has lost another notable member with the March 12 passing of Steven Wagner of the University of California, San Diego. Wagner, 64, died of heart failure after battling the condition for four months. He pio

Mark Smith, 45, Is Struck and Killed by Hit-and-Run Driver

COMMUNITY NEWS 2010-12-21 Community News Updated 22 December 2010. View In Memory: Mark A. Smith on the Journal of Alzheimer's Disease website. Mark A. Smith 21 December 2010. As shocked researchers notify each other privately, the Alzforum editors are saddened to inform the

And Then There Were Three: Donanemab Phase 3 Trial Positive

RESEARCH NEWS 2023-05-04 Research News Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly press release. The treatment slowed decline

Neuropathologist Charles Duyckaerts Passes Away at Age 70

COMMUNITY NEWS 2022-08-12 Community News After several years of battling illness, Charles Duyckaerts, a stalwart of dementia neuropathology, passed away August 6. He was 70. Perhaps best known for his work on the spread of neurofibrillary tangles, Duyckaerts also studied amyloid p

Biogen/Eisai Halt Phase 3 Aducanumab Trials

RESEARCH NEWS 2019-03-21 Research News Today, Biogen and Eisai announced they would terminate the Phase 3 ENGAGE and EMERGE trials of aducanumab for early Alzheimer’s disease. A futility analysis run by an independent data-monitoring committee concluded that that trials would not

Drilling Down into the CMS Aduhelm Decision—A Primer

COMMUNITY NEWS 2022-04-22 Community News The verdict is in—but what now? The Centers for Medicare and Medicaid Services will only cover aducanumab in the context of a clinical trial. Impassioned lobbying on both sides of the issue moved the agency to make a few changes from its dr

Current Filters

  • TYPE: News x
  • Date Range : All x

Remove all filters

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE
TYPE OF NEWS
DISEASE
TOPIC
BIOMOLECULE